Literature DB >> 16879296

Avascular necrosis of the bones: an overlooked complication of pulse steroid treatment of multiple sclerosis.

Pinar Ce1, Muhtesem Gedizlioglu, Fazýl Gelal, Pinar Coban, Gulriz Ozbek.   

Abstract

The most common cause avascular osteonecrosis (AVN) is corticosteroid medication. However, the impact of pulse steroid therapy on AVN development is not known properly. We intended to investigate the effect of this therapy on AVN development in multiple sclerosis (MS) patients. MS patients without AVN, chronic alcoholism, thrombophilia, sickle cell anemia, inflammatory bowel disease, cytotoxic drug usage history participated in the study. All of the patients were ambulatory (EDSS < 4). Thirty-three MS patients who received pulse steroid therapy at least 10 g or at least 15 g during the course of the whole disease, were the treatment group and 27 MS patients who did not receive any steroid therapy were the control group. There was no statistical difference between groups for age, sex and disease duration. Bilateral femoral magnetic resonance imaging (MRI) was performed to the both groups. In the treatment group, five patients (15.5%) had AVN whilst no AVN was found in the control group. In conclusion, it is interesting to find AVN at such a high rate in the MS patients who received pulse steroid therapy without any AVN history or complaint. The neurologists have to be more careful about AVN which early diagnosis is important to prevent the complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879296     DOI: 10.1111/j.1468-1331.2006.01375.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  11 in total

Review 1.  Steroid induced osteonecrosis: An analysis of steroid dosing risk.

Authors:  Christian Powell; Christopher Chang; Stanley M Naguwa; Gurtej Cheema; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2010-07-09       Impact factor: 9.754

2.  Avascular necrosis of the femoral head in multiple sclerosis: report of five patients.

Authors:  M A Sahraian; S Yadegari; R Azarpajouh; M Forughipour
Journal:  Neurol Sci       Date:  2011-12-31       Impact factor: 3.307

3.  A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms.

Authors:  In Young Choi; Laura Piccio; Patra Childress; Bryan Bollman; Arko Ghosh; Sebastian Brandhorst; Jorge Suarez; Andreas Michalsen; Anne H Cross; Todd E Morgan; Min Wei; Friedemann Paul; Markus Bock; Valter D Longo
Journal:  Cell Rep       Date:  2016-05-26       Impact factor: 9.423

Review 4.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

5.  Bilateral whirlbone necrosis in a young multiple sclerosis patient.

Authors:  Edvina Galiè; Bruno Jandolo
Journal:  Neurol Sci       Date:  2010-04       Impact factor: 3.307

6.  Correlation of cumulative corticosteroid treatment with magnetic resonance imaging assessment of avascular femoral head necrosis in patients with multiple sclerosis.

Authors:  Nilufer Kale; Jale Agaoglu; Osman Tanik
Journal:  Neurol Int       Date:  2010-11-26

7.  The Pathophysiological Sequence of Glucocorticoid-Induced Osteonecrosis of the Femoral Head in Male Mice.

Authors:  Robert S Weinstein; Erin A Hogan; Michael J Borrelli; Serguei Liachenko; Charles A O'Brien; Stavros C Manolagas
Journal:  Endocrinology       Date:  2017-11-01       Impact factor: 4.736

Review 8.  Corticosteroid-induced Osteonecrosis of the Femoral Head: Detection, Diagnosis, and Treatment in Earlier Stages.

Authors:  Li-Hua Liu; Qing-Yu Zhang; Wei Sun; Zi-Rong Li; Fu-Qiang Gao
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

9.  How to run a multiple sclerosis relapse clinic.

Authors:  Emma C Tallantyre; Mark Wardle; Neil P Robertson
Journal:  Pract Neurol       Date:  2015-11-11

10.  Silent osteonecrosis of the femoral head following high-dose corticosteroids in patients with systemic rheumatic diseases.

Authors:  Nahid Kianmehr; Ali Bidari; Mani Mofidi; Nasim Bahar
Journal:  Med J Islam Repub Iran       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.